Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志
中国生物工程杂志  2017, Vol. 37 Issue (12): 90-95    DOI: 10.13523/j.cb.20171213
综述     
靶向Glypican-3的肝癌免疫治疗研究进展*
余琳1,2,王建华2*,葛良鹏1,3,4*
1 重庆市畜牧科学院 重庆 402460
2 重庆大学生物工程学院 重庆 400044
3 农业部养猪科学重点实验室 重庆 402460
4 养猪科学重庆市市级重点实验室 重庆 402460
Advance in Immunotherapy Research of Hepatocellular Carcinoma Targeting Glypican-3
Lin YU1,2,Jian-hua WANG2*,Liang-peng GE1,3,4*
1 Chongqing Academy of Animal Sciences,Chongqing 402460, China
2 Bioengineering College of Chongqing University, Chongqing 400044, China
3 Key Laboratory of Pig Industry Sciences, Ministry of Agriculture,Chongqing 402460, China
4 Chongqing Key Laboratory of Pig Industry Sciences,Chongqing 402460, China
 全文: PDF(530 KB)   HTML
摘要：

磷脂酰肌醇蛋白聚糖3 (Glypican-3)蛋白高特异性表达于肝细胞肝癌患者中,研究表明其与肝癌的发展和转移关系密切。目前以Glypican-3蛋白为靶点治疗肝癌的免疫研究主要包括治疗性抗体开发、CAR-T免疫疗法、免疫毒素及多肽疫苗等。现对Glypican-3的结构功能与肝癌的关系进行介绍,并简要描述靶向Glypican-3治疗肝癌的研究现状。
关键词： Glypican-3;  肝癌;  免疫治疗;  抗体;  CAR-T    
Abstract:

Researchs shows that Glypican-3 expresses in hepatocellular carcinoma (HCC) patients with high specificity and is closely related to development of hepatocarcinoma. Including therapeutic antibody,Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) , immunotoxin and vaccine are the focus of targeting Glypican-3 for immunotherapy in HCC at present. The structure and function of Glypican-3 is reviewed, as well as the progress of immunotherapy based on Glypican-3 in HCC is briefly described.
Key words: Glypican-3    HCC    Immunotherapy    Antibody    CAR-T
收稿日期: 2017-06-22 出版日期: 2017-12-16
ZTFLH:  Q819  
基金资助: * 重庆市五大功能区域人源化抗体开发创新创业团队(17301)、重庆市农发资金(17406)资助项目
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
余琳
王建华
葛良鹏

引用本文:

余琳,王建华,葛良鹏. 靶向Glypican-3的肝癌免疫治疗研究进展*[J]. 中国生物工程杂志, 2017, 37(12): 90-95.

Lin YU,Jian-hua WANG,Liang-peng GE. Advance in Immunotherapy Research of Hepatocellular Carcinoma Targeting Glypican-3. China Biotechnology, 2017, 37(12): 90-95.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20171213    或    https://manu60.magtech.com.cn/biotech/CN/Y2017/V37/I12/90

图1  Glypican-3结构简图
图2  Glypican-3促进HCC发展作用机制
名称抗体类型研究阶段文献
GC33IgG,人源化临床二期(已完成)[33-36]
YP7IgG,人源化临床前[37]
HN3VH-hFc,全人源临床前[38]
HS20scFv,全人源临床前[40, 53]
ERY974GPC3/CD3-bispecific antibody,人源化临床一期https://clinicaltrials.gov/NCT02748837
表1  靶向Glypican-3的肝癌治疗性抗体研究
临床标识号开始时间研究阶段联合治疗研究机构
NCT023952502015年3月临床一期(已终止)无上海仁济医院
NCT027239422015年6月临床一期无广州复大肿瘤医院
NCT027153622016年3月临床一期无上海吉凯基因化学公司
NCT031307122017年4月临床一期无上海吉凯基因化学公司
NCT031462342017年3月临床一期无上海仁济医院
上海科济生物医药公司
NCT030843802017年6月临床一期肝肿瘤经动脉化疗栓塞
(氟达拉滨、环磷酰胺)		重庆新桥医院
NCT029051882018年1月临床一期淋巴细胞删除性化疗
(氟达拉滨、环磷酰胺)		美国贝勒医学院
表2  临床靶向Glypican-3治疗肝癌的CAR-T研究
[1] Torre L A, Bray F, Siegel R L, et al.Global cancer statistics, 2012 . CA: A Cancer Journal for Clinicians, 2015, 65(2): 87-108.
doi: 10.3322/caac.21262
[2] Torre L A, Siegel R L, Ward E M, et al.Global cancer incidence and mortality rates and trends—an update. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2016, 25(1): 16-27.
[3] Galle P R.Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war. J Hepatol, 2008, 49(5): 871-873.
doi: 10.1016/j.jhep.2008.09.001 pmid: 18817997
[4] Ohri N, Kaubisch A, Ggrg M, et al.Targeted therapy for hepatocellular carcinoma. Semin Radiat Oncol, 2016, 26(4): 338-343.
doi: 10.1016/j.semradonc.2016.06.004 pmid: 27619254
[5] Filmus J, Shi W, Wong Z M, et al.Identification of a new membrane-bound heparan sulphate proteoglycan. The Biochemical Journal, 1995, 311( Pt 2):561-565.
doi: 10.1042/bj3110561 pmid: 7487896
[6] Filmus J, Capurro M, Rast J.Glypicans. Genome Biology, 2008, 9(5): 224.
doi: 10.1186/gb-2008-9-5-224
[7] Hippo Y, Watanabe K, Watanabe A, et al.Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Research, 2004, 64(7): 2418-2423.
doi: 10.1158/0008-5472.CAN-03-2191
[8] Ho M, Kim H.Glypican-3: a new target for cancer immunotherapy. European Journal of Cancer, 2011, 47(3): 333-338.
doi: 10.1016/j.ejca.2010.10.024 pmid: 3031711
[9] Filmus J, Church J G, Buick R N.Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Molecular and Cellular Biology, 1988, 8(10): 4243-4249.
doi: 10.1128/MCB.8.10.4243 pmid: 365496
[10] Song H H, Filmus J.The role of glypicans in mammalian development. Biochimica et Biophysica Acta, 2002, 1573(3): 241-246.
doi: 10.1016/S0304-4165(02)00390-2 pmid: 12417406
[11] Iglesias B V, Centeno G, Pascuccelli H, et al.Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histology and Histopathology, 2008, 23(11): 1333-1340.
doi: 10.1016/j.heares.2008.09.003 pmid: 18785116
[12] Pilia G, Hughesbenzie R M, Mackenzie A, et al.Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nature Genetics, 1996, 12(3): 241-247.
doi: 10.1038/ng0396-241
[13] Song H H, Shi W, Filmus J.OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. The Journal of Biological Chemistry, 1997, 272(12): 7574-7577.
doi: 10.1074/jbc.272.12.7574 pmid: 9065409
[14] Veugelers M, Cat B D, Muyldermans S Y, et al.Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene. Human Molecular Genetics, 2000, 9(9): 1321-1328.
doi: 10.1007/BF02864550 pmid: 10814714
[15] Capurro M I, Xu P, Shi W, et al.Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Developmental Cell, 2008, 14(5): 700-711.
doi: 10.1016/j.devcel.2008.03.006 pmid: 18477453
[16] Filmus J.Glypicans in growth control and cancer. Glycobiology, 2001, 11(3): 19-23.
doi: 10.1093/glycob/11.3.19R pmid: 11320054
[17] Xiang Y Y, Ladeda V, Filmus J.Glypican-3 expression is silenced in human breast cancer. Oncogene, 2001, 20(50): 7408-7412.
doi: 10.1038/sj.onc.1204925 pmid: 11704870
[18] Wichert A, Stege A, Midorikawa Y, et al.Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene, 2004, 23(4): 945-955.
doi: 10.1111/j.1440-1827.2006.01962.x pmid: 14661052
[19] Lin H, Huber R, Schlessinger D, et al.Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res, 1999, 59(4): 807-810.
doi: 10.1136/injuryprev-2012-040686 pmid: 10029067
[20] Murthy S S, Shen T, De Rienzo A, et al.Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene, 2000, 19(3): 410-416.
doi: 10.1038/sj.onc.1203322
[21] Sung Y K, Hwang S Y, Park M K, et al.Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Science, 2003, 94(3): 259-262.
doi: 10.1016/j.healun.2007.07.015 pmid: 12824919
[22] Baumhoer D, Tornillo L, Stadlmann S, et al.Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4 387 tissue samples. American Journal of Clinical Pathology, 2008, 129(6): 899-906.
doi: 10.1309/HCQWPWD50XHD2DW6
[23] Hsu H C, Cheng W, Lai P L.Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res, 1997, 57(22): 5179-5184.
pmid: 9371521
[24] Zhu Z W, Friess H, Wang L, et al.Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48(4): 558-564.
doi: 10.1136/gut.48.4.558 pmid: 11247902
[25] Yamauchi N, Watanabe A, Hishinuma M, et al.The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Modern Pathology, 2005, 18(12): 1591-1598.
doi: 10.1038/modpathol.3800436 pmid: 15920546
[26] Haruyama Y, Yorita K, Yamaguchi T, et al.High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer, 2015, 137(7): 1643-1651.
doi: 10.1002/ijc.29518 pmid: 25784484
[27] Capurro M I, Xiang Y-Y, Lobe C, et al.Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Research, 2005, 6245-6254.
doi: 10.1158/0008-5472.CAN-04-4244 pmid: 16024626
[28] Capurro M, Martin T, Shi W, et al.Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. Journal of Cell Science, 2014, 127(Pt 7): 1565-1575.
doi: 10.1242/jcs.140871 pmid: 24496449
[29] Wands J R, Kim M.WNT/beta-catenin signaling and hepatocellular carcinoma. Hepatology, 2014, 60(2): 452-454.
doi: 10.1002/hep.v60.2
[30] Hann S R.Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Seminars in Cancer Biology, 2006, 16(4): 288-302.
doi: 10.1016/j.semcancer.2006.08.004 pmid: 16938463
[31] Li L, Jin R, Zhang X, et al.Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology, 2012, 56(4): 1380-1390.
doi: 10.1002/hep.25891 pmid: 22706665
[32] Wu Y, Liu H, Weng H, et al.Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. International Journal of Oncology, 2015, 46(3): 1275-1285.
doi: 10.3892/ijo.2015.2827 pmid: 255726153
[33] Ishiguro T, Sugimoto M, Kinoshita Y, et al.Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res, 2008, 68(23): 9832-9838.
doi: 10.1158/0008-5472.CAN-08-1973 pmid: 19047163
[34] Nakano K, Orita T, Nezu J, et al.Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun, 2009, 378(2): 279-284.
doi: 10.1016/j.bbrc.2008.11.033 pmid: 19022220
[35] Nakano K, Ishiguro T, Konishi H, et al.Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anti Cancer Drugs, 2010, 21(10): 907-916.
doi: 10.1097/CAD.0b013e32833f5d68 pmid: 20847643
[36] Abou-Alfa G K, Pyig O, Daniele B, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol, 2016, 65(2): 289-295.
doi: 10.1016/j.jhep.2016.04.004 pmid: 27085251
[37] Phung Y, Gao W, Man Y G, et al.High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. mAbs, 2012, 4(5): 592-599.
doi: 10.4161/mabs.20933 pmid: 22820551
[38] Feng M, Gao W, Wang R, et al.Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 2013, 110(12): 1083-1091.
doi: 10.1073/pnas.1214255110
[39] Hanaoka H, Nagaya T, Sato K, et al.Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Molecular Pharmaceutics, 2015, 12(6): 2151-2157.
doi: 10.1021/acs.molpharmaceut.5b00132 pmid: 25955255
[40] Wong C M, Gao W, Kim H, et al.Human monoclonal antibody targeting the heparan sulfate chains of glypican-3 inhibits HGF-mediated migration and motility of hepatocellular carcinoma cells. PloS One, 2015, 10(9): e0137664.
doi: 10.1371/journal.pone.0137664 pmid: 4557904
[41] Couzin-Frankel J.Breakthrough of the year 2013. cancer immunotherapy. Science, 2013, 342(6165): 1432-1433.
doi: 10.1126/science.342.6165.1432
[42] Gao H, Li K, Tu H, et al.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clinical Cancer Research, 2014, 20(24): 6418-6428.
doi: 10.1158/1078-0432.CCR-14-1170 pmid: 25320357
[43] Jiang Z, Jiang X, Chen S, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Frontiers in Immunology, 2016, 7:1-10.
doi: 10.3389/fimmu.2016.00690 pmid: 28123387
[44] Roybal K T, Rupp L J, Morsut L, et al.Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell, 2016, 164(4): 770-779.
doi: 10.1016/j.cell.2016.01.011 pmid: 26830879
[45] Chen C, Li K, Jiang H, et al.Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunology, Immunotherapy : CII, 2017, 66(4): 475-489.
doi: 10.1007/s00262-016-1949-8 pmid: 28035433
[46] Gao W, Tang Z, Zhang Y F, et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nature Communications, 2015, 6:1-26.
doi: 10.1038/ncomms7536 pmid: 4357278
[47] Wang C, Gao W, Feng M, et al.Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. Oncotarget, 2017, 8(20): 32450-32460.
doi: 10.18632/oncotarget.10592 pmid: 27419635
[48] Komori H, Nakatsura T, Senju S, et al.Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clinical Cancer Research, 2006, 12(9): 2689-2697.
doi: 10.1158/1078-0432.CCR-05-2267 pmid: 16675560
[49] Motomura Y, Ikuta Y, Kuronuma T, et al.HLA-A2 and-A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice. Int J Oncol, 2008, 32(5): 985-990.
doi: 10.1046/j.1460-9568.2003.02964.x pmid: 18425324
[50] Iwama T, Horie K, Yoshikawa T, et al.Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. Int J Oncol, 2013, 42(3): 831-838.
doi: 10.3892/ijo.2013.1793 pmid: 23354275
[51] Sawada Y, Yoshikawa T, Nobuoka D, et al.Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clinical Cancer Research, 2012, 18(13): 3686-3696.
doi: 10.1158/1078-0432.CCR-11-3044 pmid: 22577059
[52] Iwama T, Uchida T, Sawada Y, et al.Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochemical and Biophysical Research Communications, 2016, 469(1): 138-143.
doi: 10.1016/j.bbrc.2015.11.084 pmid: 26616051
[53] Gao W, Kim H, Feng M, et al.Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology, 2014, 60(2): 576-587.
doi: 10.1002/hep.26996 pmid: 244929433
[54] Neves H, Kwok H F.Recent advances in the field of anti-cancer immunotherapy. BBA Clinical, 2015, 3:280-288.
doi: 10.1016/j.bbacli.2015.04.001 pmid: 935
[55] Feng M, Kim H, Phung Y, et al.Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. International Journal of Cancer, 2011, 128(9): 2246-2247.
doi: 10.1002/ijc.25549 pmid: 20617511
[56] Wang H L, Anatelli F, Zhai Q J, et al.Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Archives of Pathology & Laboratory Medicine, 2008, 132(11): 1723-1728.
doi: 10.1043/1543-2165-132.11.1723 pmid: 18976006
[57] Qin Z, Wang J, Wang Y, et al. Identification of a glypican-3-binding peptide for in vivo non-invasive human hepatocellular carcinoma detection. Macromolecular Bioscience, 2016,1-10.
doi: 10.1002/mabi.201600335 pmid: 27862961
[58] Sawada Y, Yisgikawa T, Ofuji K, et al.Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology, 2016, 5(5): e1129483.
doi: 10.1080/2162402X.2015.1129483 pmid: 27467945
[1] 陈修月,周文锋,何庆,苏冰,邹亚文. 噬菌体Qβ病毒样颗粒的制备、纯化及鉴定[J]. 中国生物工程杂志, 2021, 41(7): 42-49.
[2] 陈文洁,苗先锋. 抗体偶联药物国内研发现状及企业布局分析[J]. 中国生物工程杂志, 2021, 41(6): 105-110.
[3] 许叶春,柳红,李剑峰,沈敬山,蒋华良. 抗新冠肺炎药物研究进展[J]. 中国生物工程杂志, 2021, 41(6): 111-118.
[4] 史瑞,严景华. 抗新型冠状病毒单克隆中和抗体药物研发进展*[J]. 中国生物工程杂志, 2021, 41(6): 129-135.
[5] 原博,王杰文,康广博,黄鹤. 双特异性纳米抗体的研究进展及其应用 *[J]. 中国生物工程杂志, 2021, 41(2/3): 78-88.
[6] 毛开云,李荣,李丹丹,赵若春,范月蕾,江洪波. 全球双特异性抗体药物研发格局分析*[J]. 中国生物工程杂志, 2021, 41(11): 110-118.
[7] 张赛,向乐,李林海,李辉军,王刚,钱纯亘. 新型冠状病毒(2019-nCoV)IgM /IgG抗体检测试剂的研制及性能评价[J]. 中国生物工程杂志, 2020, 40(8): 1-9.
[8] 赵妍淑,张金华,宋浩. 工程原核生物和酵母菌中生产单克隆抗体和抗体片段研究进展 *[J]. 中国生物工程杂志, 2020, 40(8): 74-83.
[9] 蔺士新,刘东晨,雷云,熊盛,谢秋玲. TNF-α纳米抗体的筛选、表达及特异性检测 *[J]. 中国生物工程杂志, 2020, 40(7): 15-21.
[10] 杨笑莹,李梦,赵威,唐敏,张志谦. 抗α2δ1/CD3双特异性抗体的制备和功能的初步研究 *[J]. 中国生物工程杂志, 2020, 40(7): 9-14.
[11] 武瑞君,李治非,张鑫,濮润,敖翼,孙燕荣. 新冠病毒抗体药物研发进展及展望分析[J]. 中国生物工程杂志, 2020, 40(5): 1-6.
[12] 王猛,宋慧茹,程雨洁,王毅,杨波,胡征. 以核糖体蛋白L7/L12为分子标志物精准检测肺炎链球菌的研究 *[J]. 中国生物工程杂志, 2020, 40(4): 34-41.
[13] 杨丽,石晓宇,李文蕾,李剑,徐寒梅. 构建噬菌体展示抗体库过程中电穿孔法的条件优化[J]. 中国生物工程杂志, 2020, 40(4): 42-48.
[14] 李彤彤,宋彩玲,杨凯越,王文静,陈慧宇,刘明. 抗犬细小病毒VP2蛋白单链抗体的制备与中和活性研究 *[J]. 中国生物工程杂志, 2020, 40(4): 10-16.
[15] 陈秋利,杨丽超,李辉,温莎,李刚,何敏. 人Nek2蛋白原核表达纯化及其多克隆抗体制备 *[J]. 中国生物工程杂志, 2020, 40(3): 31-37.
主管：中国科学院 　主办：中国科学院文献情报中心 　中国生物技术发展中心 　中国生物工程学会